[Interferon beta 1-a in multiple sclerosis: 1-year experience in 62 patients]

Arq Neuropsiquiatr. 2000 Jun;58(2B):452-9. doi: 10.1590/s0004-282x2000000300009.
[Article in Portuguese]

Abstract

We report the results of a trial of interferon beta 1-a in 62 ambulatory patients with relapsing-remitting multiple sclerosis. Entry criteria included EDSS of 0 to 5.5 and at least two exacerbations in the previous 2 years. The patients received 3 million international units by subcutaneous injections three times a week. The end points were differences in exacerbation rate and treatment effect on disease progression. The annual exacerbation rate for patients that did not take the interferon beta 1-a was 1.32 and for the patients under medication 0.63. The EDSS score in patients that did not take the mediaction was 4.7 and 2.0 for the patients with interferon beta 1-a. Interferon beta 1-a was well tolerated and 85% of patients completed 1 year treatment.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Adolescent
  • Adult
  • Age of Onset
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Interferon beta-1a
  • Interferon-beta / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Treatment Outcome

Substances

  • Adjuvants, Immunologic
  • Interferon-beta
  • Interferon beta-1a